Abstract 160P
Background
Hormonal BCs are characterized by the expression of hormonal receptors (estrogen or progesterone). They can be treated with endocrine therapy (ET) including anti-aromatase inhibitors (AI) and/or anti-cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. However, such treatments can cause cancer cells to mutate and impact genes such as ESR1, PIK3CA and/or AKT1, which are associated with ET resistance. By establishing the baseline level of these mutations in Formalin-Fixed Paraffin-Embedded (FFPE) DNA from patients with advanced or metastatic BC treated with AI and CDK4/6 inhibitors, the CICLADES-CE study, ancillary to CICLADES trial aims to identify genomic signatures to be monitored during follow-up of clonal evolution.
Methods
Twenty FFPE samples from female patients diagnosed with advanced BCs and treated with AI were qualified, selected and microdissected. The AllPrep® DNA/RNA FFPE kit (Qiagen) was used to extract DNA. A method of Hybridization Capture-based Target Enrichment with a 516-gene panel was used on the NextSeq 550® (Illumina) for sequencing. Single nucleotide variants, copy number variants and telomere length were detected. Data obtained were then analyzed to identify highly mutated genes, specific mutations in genes of interest and genomic signatures as described by Alexandrov et al, 2013.
Results
Among 20 samples, 19 reached the quality criteria to be sequenced. We showed that several genes involved in the PI3-Kinase pathway were mutated across several samples, but no relevant mutations of AKT and ESR1 were found at baseline. Among the samples, 3 genomic signatures were detected, corresponding to validated COSMIC (Catalogue of Somatic Mutations in Cancer) signatures 5, 6 and 30. Those signatures are associated with DNA damage repair and deficiency of the base excision repair system.
Conclusions
The signatures found are a mirror of the samples origin and the type of fixation used. With this information we have created a focused gene panel to be used for ctDNA follow-up analysis. It also provides us with a clear baseline mutational landscape for the profiling of the rest of the CICLADES cohort.
Editorial acknowledgement
Clinical trial identification
CIrCuLAting Dna ESr1 Gene Mutations Analysis (CICLADES): NCT03318263 First posted: October 23, 2017.
Legal entity responsible for the study
Institut de Cancérologie de Lorraine, Service de Biopathologie, CNRS UMR 7039 CRAN Université de Lorraine.
Funding
Cancéropôle de l'Est and AstraZeneca.
Disclosure
V. Massard: Financial Interests, Personal, Advisory Board: AstraZeneca, Novartis, Eli Lilly, Pfizer, Bayer; Financial Interests, Personal, Invited Speaker: Gilead Sciences, Astellas Pharma, Janssen Pharmaceuticals, Laboratoires Pierre Fabre; Financial Interests, Institutional, Funding: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
20P - Effects of <italic>Apis dorsata</italic> honey on the expression of selected CYP450, pro-apoptotic, and anti-apoptotic genes during induced cytotoxicity in cyclophosphamide-treated human lung carcinoma (A549) cells
Presenter: Jose Kenneth Narag
Session: Cocktail & Poster Display session
Resources:
Abstract
21P - Hsa_circ_0009061 inhibits the progression of bladder cancer through the miR-889-3p/CPEB3 axis
Presenter: Minkang Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
22P - Exploring exportin-1 as a therapeutic vulnerability in lung squamous cell carcinoma
Presenter: Vidushi Durani
Session: Cocktail & Poster Display session
Resources:
Abstract
23P - Identification of HPSE as potential novel therapeutic target for lung adenocarcinoma patients
Presenter: Samuel Doré
Session: Cocktail & Poster Display session
Resources:
Abstract
24P - High-throughput plasma proteomics profiling in early breast cancer
Presenter: Isabella Lombardo
Session: Cocktail & Poster Display session
Resources:
Abstract
25P - Immunohistochemical analysis of ROR1 and BMI-1 expression in luminal breast cancer
Presenter: Sergey Vtorushin
Session: Cocktail & Poster Display session
Resources:
Abstract
26P - Associations between cancer stem cells (CSC) markers and androgen (AR) and estrogen (ER) receptors expression in prostate cancer (PCa)
Presenter: Marina Puchinskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
27P - Proteomic profiling reveals organ-specific differences in metastases and identifies potential biomarkers for recurrence risk in localized colon cancer
Presenter: Blanca García-Micó
Session: Cocktail & Poster Display session
Resources:
Abstract
28P - Collagen-activated signalling pathway is significantly hypermethylated in high-grade serous ovarian cancer (HGSOC) patients treated with platinum-containing neoadjuvant chemotherapy (NACT)
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract
29P - Quantitative tissue analysis reveal adenylate kinase 2 protein signatures: Therapeutic target for meningioma
Presenter: Rashmi Rana
Session: Cocktail & Poster Display session
Resources:
Abstract